Phosphodiesterase 3A (for clinical antiplatelet targeting; otherwise "Phosphodiesterase" is a family name) (PDE3A (when referring to the most relevant enzyme in platelets))

Phosphodiesterases are a family of enzymes that hydrolyze cyclic nucleotides, such as cAMP and cGMP, thereby regulating intracellular second messenger levels that control signal transduction and platelet activation. Platelets express several types of PDEs (notably PDE2, PDE3, and PDE5) that limit the inhibitory action of cAMP and cGMP on platelet function. Pharmacological inhibition of platelet PDEs, chiefly PDE3A, is a validated strategy for antiplatelet therapy, exemplified by drugs like cilostazol, dipyridamole, and anagrelide. These agents increase intracellular cyclic nucleotide levels, limit platelet aggregation, and are used to treat and prevent thrombotic and some proliferative disorders. The specificity of PDE isoforms determines the efficacy and safety profile of inhibitors, with potential for off-target effects and adverse reactions depending on tissue distribution and individual drug properties

Other names

Phosphodiesterase (PDE)PDE2PDE3PDE5cAMP phosphodiesterase

PDE inhibition increases intracellular cAMP/cGMP, inhibiting platelet aggregation - cAMP and cGMP signal transduction modulation reduces platelet activation